Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
Fish and Richardson
Cipla
Chinese Patent Office
Accenture
US Army
Novartis
Healthtrust
Cerilliant

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205098

« Back to Dashboard

NDA 205098 describes VARITHENA, which is a drug marketed by Provensis and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the VARITHENA profile page.

The generic ingredient in VARITHENA is polidocanol. Two suppliers are listed for this compound. Additional details are available on the polidocanol profile page.
Summary for 205098
Tradename:VARITHENA
Applicant:Provensis
Ingredient:polidocanol
Patents:14
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 205098
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098 NDA Biocompatibles, Inc. 60635-118 N 60635-118-01
VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098 NDA Biocompatibles, Inc. 60635-123 E 60635-123-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength180MG/18ML (10MG/ML)
Approval Date:Nov 25, 2013TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:May 26, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
Patent:➤ Sign UpPatent Expiration:Jul 19, 2022Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:May 26, 2020Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Chinese Patent Office
Queensland Health
US Department of Justice
UBS
AstraZeneca
Dow
Covington
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot